Biomarker ID | 394 |
PMID | 18974881 |
Year | 2008 |
Biomarker | Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Gleason Score <7 Vs Gleason Score ≥ 7 |
Type of Biomarker | Prognostic |
Cohort | 41 patients were diagnosed with CaP. 66 specimens were recieved out of which 44 were benign-Cancerous pairs from the same patient. 35 were classifed as benign and 31 were classified as Prostate Cancer. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | 71% |
Level Of Significance | NA |
Method Used | RT- qPCR |
Clinical | No |
Remarks | 10 fold cross validation was applied. And Nearest Neighor technique was applied to the signature. Individually only Clusterin showed significant differential expression, but together as a signature it has good predictive power |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |